Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedJun 29, 2026
DataAggregated Company Financials
Companies17
  • 7D6.5%
  • 3M-3.3%
  • 1Y32.3%
  • YTD4.6%

Over the last 7 days, the Pharma industry has risen 6.5%, driven by gains from AstraZeneca of 7.7%. This takes the industry's 12 month performance to a gain of 32%. As for the next few years, earnings are expected to grow by 10% per annum.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 29 Jun 2026UK£337.3bUK£92.8bUK£16.0b18.4x21.1x3.6x
Wed, 27 May 2026UK£329.3bUK£91.9bUK£15.8b18.2x20.9x3.6x
Fri, 24 Apr 2026UK£344.9bUK£90.4bUK£15.5b18.8x22.2x3.8x
Sun, 22 Mar 2026UK£331.8bUK£90.8bUK£15.7b21.4x21.2x3.7x
Tue, 17 Feb 2026UK£364.7bUK£89.8bUK£15.3b24x23.8x4.1x
Thu, 15 Jan 2026UK£336.2bUK£89.4bUK£14.6b21.4x23x3.8x
Sat, 13 Dec 2025UK£319.1bUK£89.8bUK£14.7b21x21.8x3.6x
Mon, 10 Nov 2025UK£309.2bUK£90.4bUK£14.8b21.1x20.9x3.4x
Wed, 08 Oct 2025UK£299.1bUK£87.8bUK£11.7b19.3x25.5x3.4x
Fri, 05 Sep 2025UK£287.1bUK£87.7bUK£11.7b22.3x24.5x3.3x
Sun, 03 Aug 2025UK£268.3bUK£88.3bUK£11.5b28.5x23.4x3x
Tue, 01 Jul 2025UK£253.5bUK£85.7bUK£10.5b25.5x24.1x3x
Thu, 29 May 2025UK£263.9bUK£86.6bUK£10.6b26.9x24.8x3x
Sat, 26 Apr 2025UK£258.4bUK£86.4bUK£9.6b27.1x27x3x
Mon, 24 Mar 2025UK£284.4bUK£87.8bUK£9.7b32.7x29.4x3.2x
Wed, 19 Feb 2025UK£285.0bUK£88.8bUK£9.5b31x30.2x3.2x
Fri, 17 Jan 2025UK£230.7bUK£76.5bUK£7.9b31.7x29.1x3x
Sun, 15 Dec 2024UK£223.9bUK£75.2bUK£7.8b31.5x28.9x3x
Tue, 12 Nov 2024UK£219.2bUK£72.7bUK£7.6b30.7x28.8x3x
Thu, 10 Oct 2024UK£249.4bUK£72.2bUK£9.0b31.1x27.6x3.5x
Sat, 07 Sep 2024UK£271.0bUK£72.0bUK£9.0b40x30.1x3.8x
Mon, 05 Aug 2024UK£266.8bUK£72.9bUK£9.0b38.9x29.6x3.7x
Wed, 03 Jul 2024UK£260.5bUK£71.6bUK£9.6b29.3x27.3x3.6x
Fri, 31 May 2024UK£264.8bUK£71.4bUK£9.6b32.2x27.7x3.7x
Sun, 28 Apr 2024UK£261.0bUK£71.8bUK£10.1b30.7x26x3.6x
Tue, 26 Mar 2024UK£239.8bUK£70.7bUK£9.8b31.4x24.6x3.4x
Thu, 22 Feb 2024UK£231.2bUK£69.7bUK£9.6b35.7x24x3.3x
Sat, 20 Jan 2024UK£238.0bUK£68.9bUK£10.7b36.2x22.3x3.5x
Mon, 18 Dec 2023UK£227.4bUK£69.0bUK£10.7b33.9x21.3x3.3x
Wed, 15 Nov 2023UK£225.6bUK£69.6bUK£10.8b53.5x21x3.2x
Fri, 13 Oct 2023UK£248.5bUK£70.7bUK£10.3b57x24x3.5x
Sun, 10 Sep 2023UK£241.0bUK£69.8bUK£10.3b53.5x23.5x3.5x
Tue, 08 Aug 2023UK£237.9bUK£68.8bUK£10.1b52.8x23.5x3.5x
Thu, 06 Jul 2023UK£233.5bUK£67.8bUK£7.9b52.7x29.6x3.4x
Price to Earnings Ratio

29.6x


Total Market Cap: UK£233.5bTotal Earnings: UK£7.9bTotal Revenue: UK£67.8bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 25.1x202420252026
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 21.1x which is lower than its 3-year average PE of 25.1x.
  • The industry is trading close to its 3-year average PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 27% per year over the last three years.
  • Revenues for these companies have grown 11% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare industry?

GB Market1.14%
Healthcare6.15%
Pharma6.48%
Pharma6.48%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AZN AstraZenecaUK£143.187.7%
+UK£15.9b		41.5%PE28.2x
GSK GSKUK£19.833.0%
+UK£2.3b		42.7%PE13.6x
HLN HaleonUK£3.485.0%
+UK£1.5b		-7.0%PE18.4x
HIK Hikma PharmaceuticalsUK£15.313.0%
+UK£93.7m		-23.0%PE10.7x
HCM HUTCHMED (China)UK£1.602.2%
+UK£30.1m		-29.5%PE4x

Latest News

AZN
UK£143.18
AstraZeneca
7D
7.7%
1Y
41.5%
INC
UK£0.018
Incanthera
7D
-2.7%
1Y
-52.0%
HCM
UK£1.60
HUTCHMED (China)
7D
2.2%
1Y
-29.5%
Narrative Update • Jun 26

HCM: Priority Oncology Approvals Will Drive Repricing Of Shares

Analysts have revised their price target on HUTCHMED (China) upward, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin, and a much lower future P/E. Together, these factors point to a higher implied equity value in £ terms.
EAH
UK£0.89
ECO Animal Health Group
7D
-0.6%
1Y
43.9%
Narrative Update • Jun 26

EAH: Higher Profitability Assumptions Will Support Stronger Future Share Performance

Analysts have raised their price target for ECO Animal Health Group from £1.36 to £1.53, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What’s in the News for ECO Animal Health Group No recent ECO Animal Health Group news items were provided in the primary source feed.
GSK
UK£19.83
GSK
7D
3.0%
1Y
42.7%
THAT
UK£0.0065
Thalia Therapeutics
7D
13.0%
1Y
73.3%
SAR
UK£0.21
Sareum Holdings
7D
-8.7%
1Y
31.3%
HIK
UK£15.31
Hikma Pharmaceuticals
7D
3.0%
1Y
-23.0%
IMM
UK£0.037
ImmuPharma
7D
-13.5%
1Y
61.7%
STX
UK£0.061
Shield Therapeutics
7D
-6.9%
1Y
96.8%
Narrative Update • Jun 23

STX: Pediatric And Pulmonary Hypertension Trials Will Support Future Upside

Analysts have trimmed their fair value estimate for Shield Therapeutics from £0.17 to £0.17 after updating their assumptions for revenue growth, profit margins and the future P/E multiple, resulting in a slightly lower price target. What's in the News for Shield Therapeutics Shield Therapeutics announced that partner MEDLEAP Pharma, a subsidiary of Vital KSK Holdings, has enrolled the first patient in a Phase II clinical trial in Japan evaluating ACCRUFeR (ferric maltol) for Pulmonary Arterial Hypertension, following prior confirmation of the development plan by Japan's Pharmaceuticals and Medical Devices Agency.
HLN
UK£3.48
Haleon
7D
5.0%
1Y
-7.0%
Narrative Update • Jun 17

HLN: Cautious Ratings And Execution Progress Will Guide Future Share Price

Haleon’s latest Narrative Update reflects a modest reset in analyst expectations, with the average price target easing in line with recent cuts to £4.30 and £3.65 from major banks as analysts factor in slightly revised assumptions on revenue growth, profit margin and future P/E multiples. Analyst Commentary on Haleon stock Recent Street research on Haleon points to a more cautious tone, with several bearish analysts trimming price targets and, in at least one case, moving to a more neutral stance on the shares.
POLB
UK£0.068
Poolbeg Pharma
7D
-8.2%
1Y
104.5%
AGY
UK£0.07
Allergy Therapeutics
7D
-3.6%
1Y
-11.9%
FUM
UK£0.005
Futura Medical
7D
-21.6%
1Y
-93.7%
NFX
UK£0.002
Nuformix
7D
11.1%
1Y
116.2%